Biotechnology
Gene editing, cancer biotechnology, regenerative medicine, longevity science and the evidence moving from laboratories into clinical care.
-
Eight-Letter DNA: Scientists Expand Nature’s Alphabet
Eight-letter DNA expands biology’s familiar alphabet. Researchers are testing how molecular machinery reads it, with useful possibilities and major limits.
-
Injectable Mini Livers: Could Tiny Grafts Support an Organ?
Injectable mini livers kept transplanted cells alive and producing proteins in mice. Here is how the grafts work—and what the study cannot yet tell us.
-
The Alzheimer’s Trial That Starts Before Memory Loss
A major trial is testing an Alzheimer’s drug in people who have no memory problems. The ambition is prevention; the evidence still has to catch up.
-
The Weight-Loss Drug That Helped Old Mice Live Longer
Semaglutide has already changed weight-loss medicine. A new study in older female mice asks a bigger question: could its benefits reach into the biology of ageing?
-
A 3D-Printed Patch for Your Knee? The First Human Test Has Begun.
Nanochon has announced the first human procedure using its 3D-printed Chondrograft knee implant. The aim is local cartilage repair; durable benefits still need testing.
-
The FDA Just Approved a Drug That Silences a Toxic Brain Protein
Zanvastro is the first FDA-approved treatment for Alexander disease. Here is how the RNA medicine works, what its small trial showed and its risks.
-
Can Grey Hair Turn Dark Again? The Biology Is Stranger Than You Think
Some human hairs have regained pigment, and mouse studies reveal why colour-producing cells can stop working. Here is what that does—and does not—mean for reversing grey hair.
-
Can a Cancer Drug Deliver Itself Straight to a Tumour? GSK Is Betting $110 Million on the Idea
HMPL-A830 links an EGFR-seeking antibody to a KRAS inhibitor. The design could concentrate a targeted drug inside cancer cells—but it has not yet shown safety or benefit in people.
-
Can a Blood Test Tell Whether a Longevity Treatment Works? 51 Studies Put Biological-Age Clocks to the Test
Researchers compared 16 epigenetic clocks across 51 human intervention studies. Some detected consistent change, many interventions produced no clear signal, and a younger score still does not prove a longer life.
-
The “Undruggable” Target Gives Way: FDA Approves Daraxonrasib for Metastatic Pancreatic Cancer
The FDA has approved the first broad RAS-targeted medicine for metastatic pancreatic cancer after a randomized Phase 3 trial showed substantially longer survival than standard chemotherapy. The result is important—but it applies to a defined group of patients and is not a cure.
-
CRISPR Nanoparticles Edited Human Blood Stem Cells Inside Mice
Researchers used CD34-targeted lipid nanoparticles to edit human blood-forming stem cells inside humanized mice. The approach reactivated fetal haemoglobin and partly restored neutrophil development—but it remains early, intrafemoral, preclinical research.
-
FDA Approves a Pill That Targets Pancreatic Cancer’s RAS Engine
Daraxonrasib nearly doubled median survival versus chemotherapy in a 500-person Phase 3 trial. Its FDA approval opens a new way to attack one of cancer’s hardest targets—but it is not a cure.